Bard PowerPort Lawsuit 2026: $40 Million Verdict, Bellwether Trials, and Who Can File

Bard's PowerPort implantable ports face more than 4,000 federal lawsuits alleging catheter fractures, infections, blood clots, and organ damage. A May 2026 bellwether ended in a defense verdict, but a September 2026 jury awarded $40 million to a plaintiff whose fractured catheter lodged in her heart. More trials are scheduled, and no global settlement exists.

What PowerPort Devices Are and What Went Wrong

A PowerPort is an implantable port — a small device placed under the skin with a catheter threaded into a vein — used to deliver chemotherapy, IV medications, and nutrition to patients needing long-term venous access. Plaintiffs allege the catheters, made from a polyurethane material known as ChronoFlex, can break down inside the body.

The alleged injuries include catheter fracture, with fragments traveling through the bloodstream and lodging in the heart or lungs; catheter migration; bloodstream infection, including sepsis; blood clots; and organ damage. Bard disputes that the devices are defective and contests causation in individual cases.

Key Facts

  • Federal cases were consolidated into MDL 3081 in the U.S. District Court for the District of Arizona, before Judge David G. Campbell, in August 2023.
  • The JPML's October 1, 2026 report showed 4,140 pending cases in the PowerPort litigation.
  • The first bellwether trial (Cook) ended in a defense verdict on May 8, 2026.
  • The second bellwether trial (Divelbliss, a catheter-fracture case) ended on September 4, 2026, with a $40 million jury verdict for the plaintiff — a 7-inch section of fractured catheter had lodged in her heart, and she suffered 2 heart attacks.
  • The third bellwether (an infection/sepsis case) went to trial October 13–30, 2026, with further bellwether trials scheduled for December 2026 and February 2027, and no global settlement has been announced.

MDL 3081: The Federal Litigation

MDL — short for multidistrict litigation — sends similar federal cases from across the country to a single court for coordinated pretrial proceedings. The PowerPort cases became MDL 3081 in August 2023, assigned to the U.S. District Court for the District of Arizona under Judge David G. Campbell, and the docket has grown to 4,140 pending cases.

Each plaintiff keeps an individual claim; consolidation simply lets one judge handle shared discovery, expert rulings, and trial scheduling. The same mechanics shaped other device dockets, including the transvaginal mesh litigation, where thousands of individual claims moved through one coordinated court.

Bellwether Trial 1: The Cook Defense Verdict

The first bellwether trial, the Cook case, ended on May 8, 2026, in a defense verdict. Bellwether trials are test cases showing both sides how juries respond to the evidence; they do not decide the remaining cases, but they strongly influence settlement negotiations. An early defense win typically strengthens the defendant's position, at least temporarily.

Early verdicts are not always predictive. In many device MDLs — including the Ethicon Physiomesh litigation — initial defense wins were followed by substantial plaintiff victories once later bellwethers presented stronger facts or refined expert testimony. The PowerPort docket followed exactly that pattern.

Bellwether Trial 2: The $40 Million Divelbliss Verdict

The second bellwether, the Divelbliss catheter-fracture case, ended on September 4, 2026, with a jury award of $40 million for the plaintiff. A 7-inch section of the fractured catheter had traveled through her bloodstream and lodged in her heart, and she suffered 2 heart attacks connected to the device failure.

The $40 million figure is a documented named verdict in a specific, identified case — not a projection of what other claims might be worth. Large bellwether verdicts tend to reset an MDL's economics: they show the defendant that juries can connect the device to catastrophic injury and give plaintiffs' negotiators a concrete data point. Whether Bard appeals remains to be seen, but the award stands on the public record.

The Infection Bellwether and Upcoming Trials

The third bellwether — an infection and sepsis case — went to trial from October 13 to October 30, 2026. Infection claims raise different questions than fracture claims: instead of a broken catheter, the jury must weigh whether the device's design or manufacturing contributed to a bloodstream infection and the sepsis that followed.

Further bellwether trials are scheduled for December 2026 and February 2027. The continued trial calendar signals that a meaningful share of the 4,140 pending cases will proceed case-by-case for now. No global settlement has been announced, so each claim stands or falls on its own evidence, and the bellwether results keep shaping expectations on both sides.

Who Can File a PowerPort Claim

A potential claimant is generally someone implanted with a Bard PowerPort device who then suffered one of the alleged injuries — catheter fracture, migration of fragments, bloodstream infection or sepsis, blood clots, or organ damage connected to the device. Medical records showing the implant and the subsequent injury are the foundation of any claim.

Time limits apply and vary by state, generally measured from when the injury was discovered or reasonably should have been — not from the implant date. Because filing criteria differ across jurisdictions, anyone who believes they were harmed should speak with a qualified attorney promptly. Similar claim standards appear in other device disputes, such as the Depo-Provera litigation. For clear explanations of how these cases develop, the Problem Solved channel covers ongoing legal disputes.

This article is for general information only and is not legal advice. Laws, deadlines, and court proceedings change over time. Consult a qualified attorney about your situation.

Who Benefits From This — and Who Does Not

With more than 4,000 federal lawsuits consolidated in MDL 3081 and no global settlement, this article helps most the people deciding whether their own PowerPort experience belongs in this litigation — and what a single verdict does and does not mean for them.

Who benefits:

  • Patients who had a PowerPort and suffered one of the alleged injuries. How: catheter fracture with fragments traveling to the heart or lungs, catheter migration, bloodstream infection including sepsis, blood clots, or organ damage are the injuries plaintiffs allege — gather implant records and medical records showing the device and the injury.
  • People reading the bellwether signals. How: the first bellwether (Cook) ended in a defense verdict on May 8, 2026, while the second (Divelbliss) ended on September 4, 2026, with a $40 million jury verdict — bellwethers do not decide the remaining cases, but they strongly influence settlement negotiations.
  • People tracking the trial calendar. How: the infection and sepsis bellwether went to trial October 13–30, 2026, with further bellwether trials scheduled for December 2026 and February 2027 — deadlines and court developments matter more than headlines.

Who does not benefit:

  • People with a PowerPort but no alleged injury. Reason: the litigation described here concerns device failures and injuries, not the implant alone.
  • Anyone expecting a set payout from the $40 million verdict. Reason: that figure is a documented verdict in one specific, identified case — a 7-inch section of fractured catheter lodged in the plaintiff's heart, with 2 heart attacks — not a projection of what other claims might be worth.
  • Anyone assuming a settlement already exists. Reason: no global settlement has been announced, and Bard disputes that the devices are defective and contests causation in individual cases.

How coordinated device dockets work is also visible in the Ethicon Physiomesh litigation, where early defense wins were followed by substantial plaintiff victories.

Frequently Asked Questions

How much was the PowerPort bellwether verdict?

The second bellwether trial (Divelbliss) ended on September 4, 2026, with a $40 million jury verdict for the plaintiff, whose fractured catheter had lodged in her heart and who suffered 2 heart attacks.

How many PowerPort cases are pending?

The JPML's October 1, 2026 report showed 4,140 pending cases in MDL 3081.

Is there a PowerPort settlement yet?

No. As of 2026, no global settlement has been announced in the PowerPort litigation; cases continue through bellwether trials and individual proceedings.

When are the next PowerPort trials?

After the October 13–30, 2026 infection/sepsis bellwether, further bellwether trials are scheduled for December 2026 and February 2027.

Who benefits most from following the PowerPort litigation, and how should they start?

Patients who had a PowerPort implant and then suffered a catheter fracture, bloodstream infection, blood clot, or organ damage benefit most. Start by gathering implant records and medical records that show the device and the injury, and by noting that each plaintiff keeps an individual claim even though cases are coordinated in MDL 3081.

Who does not benefit from the PowerPort litigation as described here?

People with a PowerPort but no alleged injury do not fit the claims described here, and nobody should treat the $40 million Divelbliss verdict as a guaranteed payout — it was one identified case, and no global settlement has been announced.

Watch on YouTube

Problem Solved on YouTube